Leslie J. Donato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leslie J. Donato has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey W. Meeusen
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States
7 shared publicationsAllan S. Jaffe
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States; Department of Cardiology, Mayo Clinic, Rochester, MN, United States
5 shared publicationsAmy K. Saenger
Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States
5 shared publications- Allan S. Jaffe
Departments of Cardiology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN (A.S.J.).
2 shared publications Amy M. Wockenfus
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
2 shared publicationsBrad S. Karon
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
2 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 28, 101664
American Heart Association lipoprotein(a) discovery project: A national initiative to advance awareness and lipoprotein(a) testing for patients with cardiovascular disease
- 12 May 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 28, 101664
Open AccessAmerican Heart Association lipoprotein(a) discovery project: A national initiative to advance awareness and lipoprotein(a) testing for patients with cardiovascular disease
- 25 April 2026
- Published by Elsevier in Clinical Biochemistry
- Vol. 143, 111125
Corrigendum to “Biological variability of lipoprotein-associated phospholipase A2 activity in healthy individuals” [Clin. Biochem. 50 (2017) 347–349]
- 25 April 2026
- Published by Elsevier in Clinical Biochemistry
- Vol. 143, 111125
Corrigendum to “Biological variability of lipoprotein-associated phospholipase A2 activity in healthy individuals” [Clin. Biochem. 50 (2017) 347–349]
- Open Access
- 6 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3156
Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations
New more effective lipid-lowering therapies have made it important to accurately determine Low-density lipoprotein-cholesterol (LDL-C) at both high and low levels. LDL-C was measured by the β-quantification reference method (BQ) (N = 40,346) and compared to Friedewald (F-LDL-C), Martin (M-LDL-C), extended Martin (eM-LDL-C) and Sampson (S-LDL-C) equations by regression analysis, error-grid analysis, and concordance with the BQ method for classification into different LDL-C treatment intervals. For triglycerides (TG) < 175 mg/dL, the four LDL-C equations yielded similarly accurate results, but for TG between 175 and 800 mg/dL, the S-LDL-C equation when compared to the BQ method had a lower mean absolute difference (mg/dL) (MAD = 10.66) than F-LDL-C (MAD = 13.09), M-LDL-C (MAD = 13.16) or eM-LDL-C (MAD = 12.70) equations. By error-grid analysis, the S-LDL-C equation for TG > 400 mg/dL not only had the least analytical errors but also the lowest frequency of clinically relevant errors at the low (190 mg/dL) LDL-C cut-points (S-LDL-C: 13.5%, F-LDL-C: 23.0%, M-LDL-C: 20.5%) and eM-LDL-C: 20.0%) equations. The S-LDL-C equation also had the best overall concordance to the BQ reference method for classifying patients into different LDL-C treatment intervals. The S-LDL-C equation is both more analytically accurate than alternative equations and results in less clinically relevant errors at high and low LDL-C levels.
- 6 December 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3156
Open AccessAccuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations
New more effective lipid-lowering therapies have made it important to accurately determine Low-density lipoprotein-cholesterol (LDL-C) at both high and low levels. LDL-C was measured by the β-quantification reference method (BQ) (N = 40,346) and compared to Friedewald (F-LDL-C), Martin (M-LDL-C), extended Martin (eM-LDL-C) and Sampson (S-LDL-C) equations by regression analysis, error-grid analysis, and concordance with the BQ method for classification into different LDL-C treatment intervals. For triglycerides (TG) < 175 mg/dL, the four LDL-C equations yielded similarly accurate results, but for TG between 175 and 800 mg/dL, the S-LDL-C equation when compared to the BQ method had a lower mean absolute difference (mg/dL) (MAD = 10.66) than F-LDL-C (MAD = 13.09), M-LDL-C (MAD = 13.16) or eM-LDL-C (MAD = 12.70) equations. By error-grid analysis, the S-LDL-C equation for TG > 400 mg/dL not only had the least analytical errors but also the lowest frequency of clinically relevant errors at the low (190 mg/dL) LDL-C cut-points (S-LDL-C: 13.5%, F-LDL-C: 23.0%, M-LDL-C: 20.5%) and eM-LDL-C: 20.0%) equations. The S-LDL-C equation also had the best overall concordance to the BQ reference method for classifying patients into different LDL-C treatment intervals. The S-LDL-C equation is both more analytically accurate than alternative equations and results in less clinically relevant errors at high and low LDL-C levels.
- 17 November 2021
- Published by Elsevier in Clinical Biochemistry
- Vol. 117, 1-3
Evaluation of the Visby medical COVID-19 point of care nucleic acid amplification test
- 17 November 2021
- Published by Elsevier in Clinical Biochemistry
- Vol. 117, 1-3
Evaluation of the Visby medical COVID-19 point of care nucleic acid amplification test
- 1 December 2020
- Published by Elsevier in Clinical Biochemistry
- Vol. 86, 45-51
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation
- 1 December 2020
- Published by Elsevier in Clinical Biochemistry
- Vol. 86, 45-51
Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation
- Open Access
- 1 October 2019
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 65 (10) , 1219
Commentary
- 1 October 2019
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 65 (10) , 1219
Open AccessCommentary
- 1 February 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (2)
Assessment of Test Performance and Potential for Environmental Contamination Associated with a Point-of-Care Molecular Assay for Group A Streptococcus in an End User Setting
Although U.S. Food and Drug Administration-approved and CLIA-waived point-of-care (POC) molecular systems are being implemented in routine clinical practice, instrument reliability, test performance in the hands of end users, and the potential for environmental contamination resulting from use of POC molecular systems have not been extensively evaluated.
- 1 February 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (2)
Assessment of Test Performance and Potential for Environmental Contamination Associated with a Point-of-Care Molecular Assay for Group A Streptococcus in an End User Setting
Although U.S. Food and Drug Administration-approved and CLIA-waived point-of-care (POC) molecular systems are being implemented in routine clinical practice, instrument reliability, test performance in the hands of end users, and the potential for environmental contamination resulting from use of POC molecular systems have not been extensively evaluated.
- 1 December 2018
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 64 (12) , 1792-1793
LIMA1: A Newly Identified Player in the Field of Cholesterol Control
Higher concentrations of LDL cholesterol (LDL-C) are causally linked to risk for cardiovascular disease (CVD). Correspondingly, lowering cholesterol leads to a proportional lowering of risk in randomized control trials. Thus, a key objective of CVD risk mitigation is lipid lowering—and the lower, the better. The Odyssey randomized control trial suggests that there is no LDL-C concentration too low for safety, and those achieving the lowest values displayed the greatest risk reduction. What complicates the matter is the multifaceted nature of lipid homeostasis. Although approximately half of cholesterol variability is controlled by genetic variability (other factors being diet and lifestyle), only a small percentage of risk has been linked to genetic variance. Furthermore, lipid screening is poor at identifying individuals with genetic lipidemias. For example, it …
- 1 December 2018
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 64 (12) , 1792-1793
LIMA1: A Newly Identified Player in the Field of Cholesterol Control
Higher concentrations of LDL cholesterol (LDL-C) are causally linked to risk for cardiovascular disease (CVD). Correspondingly, lowering cholesterol leads to a proportional lowering of risk in randomized control trials. Thus, a key objective of CVD risk mitigation is lipid lowering—and the lower, the better. The Odyssey randomized control trial suggests that there is no LDL-C concentration too low for safety, and those achieving the lowest values displayed the greatest risk reduction. What complicates the matter is the multifaceted nature of lipid homeostasis. Although approximately half of cholesterol variability is controlled by genetic variability (other factors being diet and lifestyle), only a small percentage of risk has been linked to genetic variance. Furthermore, lipid screening is poor at identifying individuals with genetic lipidemias. For example, it …
- 1 August 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 58, 72-77
Analytical performance of an immunoassay to measure proenkephalin
- 1 August 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 58, 72-77
Analytical performance of an immunoassay to measure proenkephalin
- 1 February 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 52, 106-111
Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry
- 1 February 2018
- Published by Elsevier in Clinical Biochemistry
- Vol. 52, 106-111
Description of analytical method and clinical utility of measuring serum 7-alpha-hydroxy-4-cholesten-3-one (7aC4) by mass spectrometry